Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Apr 20097:00 amRNSIssue of Equity
31st Mar 200910:49 amRNSTotal Voting Rights
26th Mar 20095:38 pmRNSNotification of Major Interest in Shares
26th Mar 200912:49 pmRNSResults of General Meeting
25th Mar 20099:30 amRNSNotification of Major Interest in Shares
25th Mar 20097:00 amRNSDistribution Agreement and Issue of Equity
25th Mar 20097:00 amRNSManufacturing Agreement
12th Mar 20097:00 amRNSFirst stage peptide studies
4th Mar 20094:07 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSEGM Circular
27th Feb 20093:09 pmRNSTotal Voting Rights
26th Feb 20097:00 amRNSHoldings in Company
19th Feb 20097:00 amRNSFurther issue of shares
18th Feb 20097:00 amRNSIssue of Equity and Shareholdings
30th Jan 200912:53 pmRNSTotal Voting Rights
26th Jan 200912:21 pmRNSDistribution agreement in Turkey
20th Jan 20095:03 pmRNSHolding(s) in Company
15th Jan 20091:43 pmRNSIssue of Equity
6th Jan 20093:23 pmRNSResults of General Meeting
5th Jan 20094:41 pmRNSIssue of Equity
31st Dec 20087:00 amRNSTotal Voting Rights
19th Dec 20084:22 pmRNSHolding(s) in Company
12th Dec 200810:47 amRNSNotice of EGM
9th Dec 20084:30 pmRNSIssue of Equity
8th Dec 200811:15 amRNSA Book on Zolpidem Effects Published
4th Dec 200810:13 amRNSFull Colostrinin Study Results published
28th Nov 20084:24 pmRNSTotal Voting Rights
26th Nov 20087:00 amRNSColostrinin Test marketing in Poland
25th Nov 20083:39 pmRNSIssue of Equity
24th Nov 20087:00 amRNSFocus on Colostrinin revenue generation
10th Nov 20087:00 amRNSIssue of Shares
4th Nov 20081:10 pmRNSShareholding
31st Oct 200810:56 amRNSTotal Voting Rights
27th Oct 20087:00 amRNSIssue of Equity
13th Oct 20085:19 pmRNSSignificant Shareholding
9th Oct 20083:59 pmRNSHolding(s) in Company
9th Oct 20087:00 amRNSEuropean Launch of Colostrinin in Cyprus
6th Oct 200812:51 pmRNSGeneral Meeting, Share Capital Sub-division
6th Oct 20087:00 amRNSZolpidem Review
2nd Oct 20082:03 pmRNSSignificant Shareholding
30th Sep 20083:44 pmRNSTotal Voting Rights
23rd Sep 20085:29 pmRNSHolding(s) in Company
23rd Sep 20085:21 pmRNSHolding(s) in Company
23rd Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSIssue of Equity
12th Sep 20087:00 amRNSGeneral Meeting
2nd Sep 20084:07 pmRNSTR-1 announcement
29th Aug 200812:33 pmRNSTotal Voting Rights
13th Aug 20087:00 amRNSPlacing
12th Aug 20087:00 amRNSFinancing and Commercial Upda

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.